Logo Logo
Switch Language to German

Hehlmann, R., Müller, M. C., Lauseker, Michael, Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, Markus, Haferlach, C., Schnittger, S., Einsele, H., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Baerlocher, Gabriela M., Ehninger, G., Heim, D., Heimpel, H., Nerl, C., Krause, S. W., Hossfeld, D. K., Kolb, H. J., Hasford, Joerg, Saußele, Susanne and Hochhaus, A. (2014): Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. In: Journal of Clinical Oncology, Vol. 32, No. 5: pp. 415-423

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item